The amount of drug use in domestic hospitals has increased, and the competitiveness of core products is becoming more and more apparent

Recently, domestic sample hospital statistics show that in 2019, the total sales of the top 50 varieties of hospital drug use amounted to 76.414 billion yuan.
, the areas involved are: anti-infective drugs amounted to 13.999 billion yuan, blood and hemagtic system drugs 12.911 billion yuan, anti-tumor drugs 11.403 billion yuan, digestive drugs 7.107 billion yuan, nervous system drugs 5,065 million yuan, the other nine areas of total drug use amounted to 25.929 billion yuan.
In addition, through the combing analysis of the growth rate of common name varieties in sample hospitals, it can be found that: 10 products with growth rate of more than 30%, 18 products with growth rate of 20% to 30%, 9 products with growth rate of 1% to 10%, and the amount of drug use of other products decreased to varying degrees.
it is worth noting that three of the products with a drug value of 1 billion to 2 billion yuan grew by more than 50%, and even one variety grew by 989.4%.
polyethyl glycol recombinant human granulocyte collection stimulation factor, the growth rate of 73.50% recombinant human granulocyte recombinant stimulator injection for the use of gene recombination technology to produce human granulocyte collection stimulation factor.
biological activity is basically the same in the body and outside compared with natural products.
rhG-CSF is one of the main cytokines that regulate granular hematosis in the bone marrow, selectively acting on granular hematoblasts, promoting their proliferation, differentiation, and increasing the function of end-of-granulation cells.
2019 polyethyl glycol recombinant human granulocyte collection stimulation factor, the amount of drug use in the sample hospital market was 1.705 billion yuan, an increase of 73.50%.
, the growth rate of 55.62% beval bead monoantin is a targeted drug suitable for a variety of tumors.
it plays its role by inhibiting the biological activity of human endothort growth factors, targeting VEGF, which can be used to reduce tumor microvascular production and inhibit the progression of metastases.
can now be used for metastatic colorectal cancer, non-small cell lung cancer (except for the treatment of lung scale cancer).
in 2019, the amount of drugs used in the sample hospital market was 1.555 billion yuan, an increase of 73.50%.
Ociltinib, a 989.4% growth Alias Terisa, or 9291, is a new drug developed by British drug company AstraZeneta for non-small cell advanced lung cancer Tagrisso (osimertinib) has been successfully marketed as an oral drug for patients with advanced non-small cell lung cancer (NSCLC).
August 17, 2018, the National Health Insurance Administration issued the Notice on the Release of the Scope of Special Negotiated Drugs for Access to Anti-Cancer Drugs 2018, in which the list of 18 anti-cancer drugs includes the lung cancer target drug Oxytini.
October 10, three months after the talks, the National Health Service announced that it would formally include 19 cancer-targeted drugs, including oxytinita, in medicare reimbursements.
2019, the amount of drugs used in the sample hospital market was 1.004 billion yuan, an increase of 73.50%.
Conclusion industry analysis believes that in the past two years, the dynamic adjustment of the medical insurance catalog, into the variety ushered in the volume, as well as innovative products to speed up, have the power to drive the growth of the overall market of sample hospitals, the future under this development trend, the competitiveness of the core products of domestic sample hospitals will be further revealed.